Stocks and Investing Stocks and Investing
Wed, June 14, 2023

Raghuram Selvaraju Reiterated (ACRS) at Strong Buy and Held Target at $43 on, Jun 14th, 2023


Published on 2024-10-28 04:21:07 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Reiterated "Aclaris Therapeutics, Inc." (ACRS) at Strong Buy and Held Target at $43 on, Jun 14th, 2023.

Raghuram has made no other calls on ACRS in the last 4 months.



There are 2 other peers that have a rating on ACRS. Out of the 2 peers that are also analyzing ACRS, 0 agree with Raghuram's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Raghuram


  • Corinne Jenkins of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $21 on, Tuesday, March 7th, 2023
  • Julian Harrison of "BTIG" Maintained at Strong Buy with Decreased Target to $29 on, Tuesday, March 7th, 2023

Contributing Sources